MSMonique A. Spillman

Monique A. Spillman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monique A. Spillman has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer

    by David N. Buckley, Juan Pablo Lewinger, Gerald Gooden, Monique Spillman, Monica Neuman, X. Mona Guo, Ben Yi Tew, Heather Miller, Varun U. Khetan, Lee P. Shulman, et al.

    Purpose:High-grade serous ovarian carcinoma (HGSOC) is the most lethal epithelial ovarian cancer (EOC) and is often diagnosed at late stage. In women with a known pelvic mass, surgery followed by pathologic assessment is the most reliable way to diagnose EOC and there are still no effective screening tools in asymptomatic women. In the current study, we developed a cell-free DNA (cfDNA) methylation liquid biopsy for the risk assessment of early-stage HGSOC.Experimental Design:We performed reduced representation bisulfite sequencing to identify differentially methylated regions (DMR) between HGSOC and normal ovarian and fallopian tube tissue. Next, we performed hybridization probe capture for 1,677 DMRs and constructed a classifier (OvaPrint) on an independent set of cfDNA samples to discriminate HGSOC from benign masses. We also analyzed a series of non-HGSOC EOC, including low-grade and borderline samples to assess the generalizability of OvaPrint. A total of 372 samples (tissue n = 59, plasma n = 313) were analyzed in this study.Results:OvaPrint achieved a positive predictive value of 95% and a negative predictive value of 88% for discriminating HGSOC from benign masses, surpassing other commercial tests. OvaPrint was less sensitive for non-HGSOC EOC, albeit it may have potential utility for identifying low-grade and borderline tumors with higher malignant potential.Conclusions:OvaPrint is a highly sensitive and specific test that can be used for the risk assessment of HGSOC in symptomatic women. Prospective studies are warranted to validate OvaPrint for HGSOC and further develop it for non-HGSOC EOC histotypes in both symptomatic and asymptomatic women with adnexal masses.

  • Open Access

    Data from OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer

    by David N. Buckley, Juan Pablo Lewinger, Gerald Gooden, Monique Spillman, Monica Neuman, X. Mona Guo, Ben Yi Tew, Heather Miller, Varun U. Khetan, Lee P. Shulman, et al.

    Purpose:High-grade serous ovarian carcinoma (HGSOC) is the most lethal epithelial ovarian cancer (EOC) and is often diagnosed at late stage. In women with a known pelvic mass, surgery followed by pathologic assessment is the most reliable way to diagnose EOC and there are still no effective screening tools in asymptomatic women. In the current study, we developed a cell-free DNA (cfDNA) methylation liquid biopsy for the risk assessment of early-stage HGSOC.Experimental Design:We performed reduced representation bisulfite sequencing to identify differentially methylated regions (DMR) between HGSOC and normal ovarian and fallopian tube tissue. Next, we performed hybridization probe capture for 1,677 DMRs and constructed a classifier (OvaPrint) on an independent set of cfDNA samples to discriminate HGSOC from benign masses. We also analyzed a series of non-HGSOC EOC, including low-grade and borderline samples to assess the generalizability of OvaPrint. A total of 372 samples (tissue n = 59, plasma n = 313) were analyzed in this study.Results:OvaPrint achieved a positive predictive value of 95% and a negative predictive value of 88% for discriminating HGSOC from benign masses, surpassing other commercial tests. OvaPrint was less sensitive for non-HGSOC EOC, albeit it may have potential utility for identifying low-grade and borderline tumors with higher malignant potential.Conclusions:OvaPrint is a highly sensitive and specific test that can be used for the risk assessment of HGSOC in symptomatic women. Prospective studies are warranted to validate OvaPrint for HGSOC and further develop it for non-HGSOC EOC histotypes in both symptomatic and asymptomatic women with adnexal masses.

  • Open Access

    OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer

    by David N. Buckley, Juan Pablo Lewinger, Gerald Gooden, Monique Spillman, Monica Neuman, X. Mona Guo, Ben Yi Tew, Heather Miller, Varun U. Khetan, Lee P. Shulman, et al.

    Purpose: High-grade serous ovarian carcinoma (HGSOC) is the most lethal epithelial ovarian cancer (EOC) and is often diagnosed at late stage. In women with a known pelvic mass, surgery followed by pathologic assessment is the most reliable way to diagnose EOC and there are still no effective screening tools in asymptomatic women. In the current study, we developed a cell-free DNA (cfDNA) methylation liquid biopsy for the risk assessment of early-stage HGSOC. Experimental Design: We performed reduced representation bisulfite sequencing to identify differentially methylated regions (DMR) between HGSOC and normal ovarian and fallopian tube tissue. Next, we performed hybridization probe capture for 1,677 DMRs and constructed a classifier (OvaPrint) on an independent set of cfDNA samples to discriminate HGSOC from benign masses. We also analyzed a series of non-HGSOC EOC, including low-grade and borderline samples to assess the generalizability of OvaPrint. A total of 372 samples (tissue n = 59, plasma n = 313) were analyzed in this study. Results: OvaPrint achieved a positive predictive value of 95% and a negative predictive value of 88% for discriminating HGSOC from benign masses, surpassing other commercial tests. OvaPrint was less sensitive for non-HGSOC EOC, albeit it may have potential utility for identifying low-grade and borderline tumors with higher malignant potential. Conclusions: OvaPrint is a highly sensitive and specific test that can be used for the risk assessment of HGSOC in symptomatic women. Prospective studies are warranted to validate OvaPrint for HGSOC and further develop it for non-HGSOC EOC histotypes in both symptomatic and asymptomatic women with adnexal masses.


  • Open Access

    Data from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

    by Monique A. Spillman, Nicole G. Manning, Wendy W. Dye, Carol A. Sartorius, Miriam D. Post, Joshua Chuck Harrell, Britta M. Jacobsen, Kathryn B. Horwitz

    Menopausal estrogen (E2) replacement therapy increases the risk of estrogen receptor (ER)–positive epithelial ovarian cancers (EOC). Whether E2 is tumorigenic or promotes expansion of undiagnosed preexisting disease is unknown. To determine E2 effects on tumor promotion, we developed an intraperitoneal mouse xenograft model using ZsGreen fluorescent ER− 2008 and ER+ PEO4 human EOC cells. Tumor growth was quantified by in vivo fluorescent imaging. In ER+ tumors, E2 significantly increased size, induced progesterone receptors, and promoted lymph node metastasis, confirming that ERs are functional and foster aggressiveness. Laser-captured human EOC cells from ER− and ER+ xenografted tumors were profiled for expression of E2-regulated genes. Three classes of E2-regulated EOC genes were defined, but <10% were shared with E2-regulated breast cancer genes. Because breast cancer selective ER modulators (SERM) are therapeutically ineffective in EOC, we suggest that our EOC-specific E2-regulated genes can assist pharmacologic discovery of ovarian-targeted SERM. Cancer Res; 70(21); 8927–36. ©2010 AACR.

  • Open Access

    Data from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

    by Monique A. Spillman, Nicole G. Manning, Wendy W. Dye, Carol A. Sartorius, Miriam D. Post, Joshua Chuck Harrell, Britta M. Jacobsen, Kathryn B. Horwitz

    Menopausal estrogen (E2) replacement therapy increases the risk of estrogen receptor (ER)–positive epithelial ovarian cancers (EOC). Whether E2 is tumorigenic or promotes expansion of undiagnosed preexisting disease is unknown. To determine E2 effects on tumor promotion, we developed an intraperitoneal mouse xenograft model using ZsGreen fluorescent ER− 2008 and ER+ PEO4 human EOC cells. Tumor growth was quantified by in vivo fluorescent imaging. In ER+ tumors, E2 significantly increased size, induced progesterone receptors, and promoted lymph node metastasis, confirming that ERs are functional and foster aggressiveness. Laser-captured human EOC cells from ER− and ER+ xenografted tumors were profiled for expression of E2-regulated genes. Three classes of E2-regulated EOC genes were defined, but <10% were shared with E2-regulated breast cancer genes. Because breast cancer selective ER modulators (SERM) are therapeutically ineffective in EOC, we suggest that our EOC-specific E2-regulated genes can assist pharmacologic discovery of ovarian-targeted SERM. Cancer Res; 70(21); 8927–36. ©2010 AACR.

  • Open Access

    Supplementary Tables 1-4 from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

    by Monique A. Spillman, Nicole G. Manning, Wendy W. Dye, Carol A. Sartorius, Miriam D. Post, Joshua Chuck Harrell, Britta M. Jacobsen, Kathryn B. Horwitz

  • Open Access

    Supplementary Figures 1-3 from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

    by Monique A. Spillman, Nicole G. Manning, Wendy W. Dye, Carol A. Sartorius, Miriam D. Post, Joshua Chuck Harrell, Britta M. Jacobsen, Kathryn B. Horwitz

  • Open Access

    Supplementary Tables 1-4 from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

    by Monique A. Spillman, Nicole G. Manning, Wendy W. Dye, Carol A. Sartorius, Miriam D. Post, Joshua Chuck Harrell, Britta M. Jacobsen, Kathryn B. Horwitz

  • Open Access

    Supplementary Figures 1-3 from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

    by Monique A. Spillman, Nicole G. Manning, Wendy W. Dye, Carol A. Sartorius, Miriam D. Post, Joshua Chuck Harrell, Britta M. Jacobsen, Kathryn B. Horwitz

    Supplementary Figures 1-3 from Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis

  • MAID ready for primetime? A survey of SGO membership regarding medical aid in dying (MAID)

    by Alaina Brown, Nefertiti Dupont, Ronald Alvarez, Monique Spillman, Lisa Landrum, Carolyn Lefkowits